Arg72Pro polymorphism (rs1042522) of the TP53 gene in patients with coronary artery disease: influence on long-term prognosis after coronary artery bypass grafting

Introduction. Investigation for genetic determinants of cardiovascular diseases takes an important place in the concept of personalized medicine. Objective. To evaluate the effect of Arg72Pro (rs1042522) polymorphism TP53 gene on long-term prognosis in patients with coronary artery disease (CAD) undergoing coronary artery bypass grafting (CABG). Materials and methods. 89 patients with stable CAD and multivessel coronary artery disease (CA) were included in the study. The first sample was 61 people who were carriers of the Arg/Arg and Arg/Pro variants. The second one was 28 people who had the Pro/Pro variant. Patients were evaluated for myocardial remodeling, quality of life, as well as clinical data for the 18-months follow-up period. Results. In carriers of the Arg/Arg and Arg/Pro variants of the TP53 gene, during the follow-up period, we obtained elevation of end-diastolic volume (EDV) and end-systolic volume (ESV) of left ventricle (LV) in the first sample: 104.4 ± 4.2 ml and 45.8±3.5 ml, one year after CABG – 113.3±5.6 ml and 52.4±4.7 ml respectively (p<0.05). Negative dynamics of EDV and LV ESV in patients of group II were not observed. Quality of life by Minnesota scale before CABG in cohort I was 27.3±2.4 points, in 18 months after – 22.6±2.1 (p=0.126). In group II: 32.8±1.9, 1,5 years later – 20.9±2.2 points (p<0.001). Acute decompensation of chronic heart failure (ADHF) in the long-term follow-up period in group I occurred in 19 (32.2 %) patients, while in group II – in 3 persons (10.7 %) (OR 3.96; 95 % CI: 1.06-14.76; p=0.036). Conclusion. Patients with the Arg/Arg and Arg/Pro variants of the TP53 gene demonstrated progression of LV remodeling, as well as a 4-fold increased risk of ADHF within 18 months after CABG. In patients with the Pro allele, quality of life after CABG improved.

1. Heusch G. Myocardial ischemia: lack of coronary blood flow, myocardial oxygen supply-demand imbalance, or what? // Am J Physiol Heart Circ Physiol. 2019;316(6):H1439–H1446. Doi: 10.1152/ajpheart.00139.2019.

2. Galagudza MM, Sonin DL, Aleksandrov IV. Myocardial hibernation: molecular mechanisms, clinical significance and diagnostic methods // Regional blood circulation and microcirculation. 2019;18(3):9–15. (In Russ.). Doi: 10.24884/1682-6655-2019-18-3-9-15.

3. Elsässer A, Vogt AM, Nef H, Kostin S, Möllmann H, Skwara W, Bode C, Hamm C, Schaper J. Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death // J Am Coll Cardiol. 2004;43(12):2191–2199. Doi: 10. 1016/j.jacc.2004.02.053.

4. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential // Nat Genet. 2003; 33(3):357–365. Doi: 10.1038/ng1093.

5. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies // Int J Cancer. 2011;129(4):920–930. Doi: 10.1002/ijc.25710.

6. Almeida A, Sánchez-Morán I, Rodríguez C. Mitochondrialnuclear p53 trafficking controls neuronal susceptibility in stroke // IUBMB Life. 2021;73(3):582–591. Doi: 10.1002/iub.2453.

7. Bonfigli AR, Sirolla C, Testa R, Cucchi M, Spazzafumo L, Salvioli S, Ceriello A, Olivieri F, Festa R, Procopio AD, Brandoni G, Boemi M, Marra M, Franceschi C. The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study // Acta Diabetol. 2013;50(3):429–436. Doi: 10.1007/ s00592-012-0450-x.

8. Reiling E, Lyssenko V, Boer JM, Imholz S, Verschuren WM, Isomaa B, Tuomi T, Groop L, Dollé ME. Codon 72polymorphism (rs1042522) of TP53 is associated with changes in diastolic blood pressure over time // Eur J Hum Genet. 2012; 20(6):696–700. Doi: 10.1038/ejhg.2011.240.

9. Kolovou V, Tsipis A, Mihas C, Katsiki N, Vartela V, Koutelou M, Manolopoulou D, Leondiadis E, Iakovou I, Mavrogieni S, Kolovou G. Tumor Protein p53 (TP53) Gene and Left Main Coronary Artery Disease. Angiology // 2018;69(8):730– 735. Doi: 10.1177/0003319718760075.

10. Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-Ramos SA, Moehnle P, Mangano DT; Investigators of the Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery // Circulation. 2007;116(5):471–479. Doi: 10.1161/CIRCULATIONAHA.106.653501.

11. Lee SI, Lee SY, Choi CH, Park CH, Park KY, Son KH. Relation between changes in red blood cell distribution width after coronary artery bypass grafting and early postoperative morbidity // J Thorac Dis. 2018;10(7):4244–4254. Doi: 10.21037/jtd.2018.06.108.

12. Zindrou D, Taylor KM, Bagger JP. Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery // Lancet. 2002;359(9319):1747–1748. Doi: 10.1016/S0140-6736(02)08614-2.

13. Hannan EL, Samadashvili Z, Lahey SJ, Culliford AT, Higgins RS, Jordan D, Gold JP, Smith CR, Wechsler A. Predictors of postoperative hematocrit and association of hematocrit with adverse outcomes for coronary artery bypass graft surgery patients with cardiopulmonary bypass // J Card Surg. 2010; 25(6):638–646. Doi: 10.1111/j.1540-8191.2010.01143.x.

14. Frentiu AA, Mao K, Caruana CB, Raveendran D, Perry LA, Penny-Dimri JC, Ramson DM, Segal R, Bellomo R, Smith JA, Liu Z. The Prognostic Significance of Red Cell Distribution Width in Cardiac Surgery: A Systematic Review and Meta-Analysis // J Cardiothorac Vasc Anesth. 2023;37(3):471– 479. Doi: 10.1053/j.jvca.2022.11.015.

15. Kertai MD, Zhou S, Karhausen JA, Cooter M, Jooste E, Li YJ, White WD, Aronson S, Podgoreanu MV, Gaca J, Welsby IJ, Levy JH, Stafford-Smith M, Mathew JP, Fontes ML. Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery // Anesthesiology. 2016;124(2):339–352. Doi: 10.1097/ALN.0000000000000959.

16. Kostenko VA, Skorodumova EA, Fedorov AN, Kiselgof OG. Influence of deteriorated renal function with elevated serum creatinin level for course of disease and prognosis of myocardinal infarction // Regional blood circulation and microcirculation. 2013;12(2):55–59. (In Russ.). Doi: 10.24884/1682-6655- 2013-12-2-55-59.

17. Fallahzadeh A, Sheikhy A, Ajam A, Sadeghian S, Pashang M, Shirzad M, Bagheri J, Mansourian S, Momtahen S, Hosseini K. Significance of preoperative left ventricular ejection fraction in 5-year outcome after isolated CABG // J Cardiothorac Surg. 2021;16(1):353. Doi: 10.1186/s13019-021-01732-3.

18. Angelini A, Maiolino G, La Canna G, Ceconi C, Calabrese F, Pettenazzo E, Valente M, Alfieri O, Thiene G, Ferrari R. Relevance of apoptosis in influencing recovery of hibernating myocardium // Eur J Heart Fail. 2007;9(4):377–383. Doi: 10.1016/j.ejheart.2006.09.012.

19. Gloria-Bottini F, Saccucci P, Magrini A, Bottini E, Banci M, Papetti F, Nardi P, Scognamiglio M, Pellegrino A, Chiariello L. p53 codon 72 polymorphism and coronary artery disease: evidence of association with left ventricular ejection fraction // Am J Med Sci. 2012;343(2):127–130. Doi: 10.1097/ MAJ.0b013e318223ac71.

20. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // J Am Soc Echocardiogr. 2016;29(4):277–314. Doi: 10.1016/j.echo.2016.01.011.

21. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group // Am Heart J. 1992;124(4):1017–1025. Doi: 10.1016/0002-8703(92)90986-6.

22. Lagares MH, Silva KSF, Barbosa AM, Rodrigues DA, Costa IR, Martins JVM, Morais MP, Campedelli FL, Moura KKVO. Analysis of p53 gene polymorphism (codon 72) in symptomatic patients with atherosclerosis // Genet Mol Res. 2017;16(3). Doi: 10.4238/gmr16039721.

23. Omrani-Nava V, Hedayatizadeh-Omran A, AlizadehNavaei R, Mokhberi V, Jalalian R, Janbabaei G, Amjadi O, Rahmatpour G, Mozaffari A. TP53 single nucleotide polymorphism (rs1042522) in Iranian patients with coronary artery disease // Biomed Rep. 2018;9(3):259–265. Doi: 10.3892/ br.2018.1121.

24. Kojima S, Iwai N, Tago N, Ono K, Ohmi K, Tsujimoto G, Takagi S, Miyazaki S, Nonogi H, Goto Y. p53Arg72Pro polymorphism of tumour suppressor protein is associated with luminal narrowing after coronary stent placement // Heart. 2004;90(9):1069–1070. Doi: 10.1136/hrt.2002.007047.

25. Bojesen SE, Nordestgaard BG. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans // Cell Cycle. 2008;7(2):158–63. Doi: 10.4161/cc.7.2.5249.